Ribociclib
Novartis
['breast']
"some of the most exciting news" at #asco23: read more in from dana-farber's sara tolaney, md, mph ( ) as she discusses a study on a drug found to cut the risk of breast cancer recurrence for some early-stage patients.
article here 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090